Department of Medicine
Chief, Section of Nephrology
Arlene Chapman is an international expert in autosomal dominant polycystic kidney disease (ADPKD). She has been responsible for the seminal observations of relative activation of the renin-angiotensin aldosterone system (RAAS) in the development of hypertension of ADPKD and the mechanisms responsible for intracranial aneurysm and liver and kidney cyst formation in this disorder. She has developed imaging biomarkers, now approved nationally, that identify patients at risk for progressive kidney and liver disease. She also has established a number of therapies to help delay progression in ADPKD, including rigorous blood pressure control, inhibitors of the RAAS, vasopressin V2-receptor antagonists, and dietary management. In addition, she has evaluated the genetic determinants of antihypertensive drug responses and their safety profiles in patients with both uncomplicated essential hypertension and individuals with difficult-to-control hypertension.
Chapman has published nearly 170 peer-reviewed articles and book chapters, and has served on the editorial boards for the American Journal of Kidney Diseases, Kidney International, and the Journal of the American Society of Nephrology.
Chapman received her MD from McMaster University. She completed her internal medicine residency and nephrology fellowship training at Georgetown University School of Medicine and her clinical research fellowship training at the University of Colorado School of Medicine. She was previously a faculty member at the University of Colorado and Emory University.